Business Context and Reporting Period
Company: NanoVibronix, Inc. (Note: Request metadata listed "Envue Medical, Inc.", but the filing identifies the registrant as NanoVibronix, Inc., which is pursuing a merger with Envue Medical Holdings, Corp.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2025 (Event Date: May 14, 2025; Closing Date: May 16, 2025)
Context: The Company entered into a material definitive agreement for an underwritten public offering of Series G Convertible Preferred Stock and warrants. This transaction is part of the capital structure adjustments related to a previously disclosed merger agreement with Envue Medical Holdings, Corp.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10 million.
- Securities Issued:
- 400,000 shares of Series G Convertible Preferred Stock (Stated Value: $25/share).
- Warrants to purchase up to 4,901,982 shares of Common Stock (Exercise Price: $2.04/share; Term: 5 years).
- Underwriting Costs: 7% of aggregate gross proceeds plus $150,000 for road show, diligence, and legal expenses.
- Representative Warrants: 245,099 warrants issued to the underwriter (Dawson James Securities, Inc.).
- Debt Repayment Plan:
- Full redemption of a $1,300,000 debenture issued February 14, 2025.
- Partial repayment of up to $700,000 of a $2,497,308 note issued January 17, 2025.
- Remaining Use of Proceeds: General corporate purposes.
Material Changes and Security Terms
Series G Preferred Stock Terms:
- Dividends: Cumulative at 9% per annum of stated value, payable in cash or Common Stock at the Company's option.
- Conversion: Convertible into Common Stock at an initial price of $2.04/share. Mandatory conversion occurs on the fifth anniversary.
- Anti-Dilution: Full ratchet protection if equity is issued below the conversion price (subject to a "Floor Price" of 50% of the Nasdaq Minimum Price).
- Make-Whole Provision: Early conversion triggers a payment for accrued but unpaid dividends.
Series X Preferred Stock Amendment:
- Authorized shares increased from 57,720 to 62,220.
- Conversion price reduced to match the Series G Preferred Stock conversion price ($2.04) upon closing of the Offering.
Lock-Up Provisions: The Company agreed not to issue additional Common Stock or convertible securities for 90 days post-closing, and no variable rate transactions for six months post-closing.
Guidance, Outlook, and Risks
Management Commentary: The filing does not provide specific forward-looking financial guidance or revenue projections. The primary strategic focus is securing capital to reduce debt obligations and fund general corporate purposes in the context of the pending merger.
Risks and Contingencies:
- Dilution: The offering introduces significant potential dilution through the conversion of Preferred Stock and the exercise of warrants (approx. 9.8 million shares of Common Stock potential).
- Dividend Obligation: The 9% cumulative dividend rate creates a recurring financial obligation that may be paid in equity, further increasing dilution.
- Anti-Dilution Adjustments: The full ratchet provision could significantly lower the conversion price if the Company issues equity at a lower price in the future, increasing the share count upon conversion.
- Merger Dependency: The transaction is linked to the merger with Envue Medical; failure of the merger could impact the strategic rationale for this capital raise.
Investor Verification Checklist
- Verify the exact closing date and final net proceeds after deducting the 7% underwriting fee and $150,000 expense.
- Confirm the current outstanding share count of Common Stock to calculate the precise dilution impact of the 400,000 Preferred Shares and 4.9 million Warrants.
- Review the "Floor Price" calculation based on the Nasdaq Minimum Price on May 14, 2025, to understand the downside protection for the conversion price.
- Assess the Company's ability to service the 9% cumulative dividend obligation if cash flow is insufficient, noting the option to pay in stock.
- Monitor the status of the merger agreement with Envue Medical Holdings, Corp., as the Series X amendment was executed in connection with this deal.